➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
Medtronic
Express Scripts
Colorcon
Dow
AstraZeneca

Last Updated: September 23, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR AGGRENOX

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

505(b)(2) Clinical Trials for Aggrenox

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
New Formulation NCT02273531 ↗ Bioequivalence of a New Asasantin Formulation Extended Release (ER) Compared to the Commercially Available Asasantin Formulation (Aggrenox┬«; Extended Release) in Healthy Male and Female Volunteers Completed Boehringer Ingelheim Phase 1 2004-01-01 Study to establish the bioequivalence of a new formulation of Asasantin ER compared to the present commercially available Asasantin ER formulation (Aggrenox┬«)
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for Aggrenox

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00067119 ↗ Vascular Access Clinical Trials Data Coordinating Center Completed Baystate Medical Center Phase 3 2003-01-01 Fistula Study: The objective of the study is to determine whether clopidogrel reduces the early failure rate of native AV fistulae. Graft Study: The objective of the study is to determine whether Aggrenox (Boehringer-Ingelheim) prolongs primary unassisted patency in newly created arteriovenous grafts.
NCT00067119 ↗ Vascular Access Clinical Trials Data Coordinating Center Completed Boston University Phase 3 2003-01-01 Fistula Study: The objective of the study is to determine whether clopidogrel reduces the early failure rate of native AV fistulae. Graft Study: The objective of the study is to determine whether Aggrenox (Boehringer-Ingelheim) prolongs primary unassisted patency in newly created arteriovenous grafts.
NCT00067119 ↗ Vascular Access Clinical Trials Data Coordinating Center Completed CAMC Health System Phase 3 2003-01-01 Fistula Study: The objective of the study is to determine whether clopidogrel reduces the early failure rate of native AV fistulae. Graft Study: The objective of the study is to determine whether Aggrenox (Boehringer-Ingelheim) prolongs primary unassisted patency in newly created arteriovenous grafts.
NCT00067119 ↗ Vascular Access Clinical Trials Data Coordinating Center Completed Duke University Phase 3 2003-01-01 Fistula Study: The objective of the study is to determine whether clopidogrel reduces the early failure rate of native AV fistulae. Graft Study: The objective of the study is to determine whether Aggrenox (Boehringer-Ingelheim) prolongs primary unassisted patency in newly created arteriovenous grafts.
NCT00067119 ↗ Vascular Access Clinical Trials Data Coordinating Center Completed Emory University Phase 3 2003-01-01 Fistula Study: The objective of the study is to determine whether clopidogrel reduces the early failure rate of native AV fistulae. Graft Study: The objective of the study is to determine whether Aggrenox (Boehringer-Ingelheim) prolongs primary unassisted patency in newly created arteriovenous grafts.
NCT00067119 ↗ Vascular Access Clinical Trials Data Coordinating Center Completed Maine Medical Center Phase 3 2003-01-01 Fistula Study: The objective of the study is to determine whether clopidogrel reduces the early failure rate of native AV fistulae. Graft Study: The objective of the study is to determine whether Aggrenox (Boehringer-Ingelheim) prolongs primary unassisted patency in newly created arteriovenous grafts.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Aggrenox

Condition Name

Condition Name for Aggrenox
Intervention Trials
Healthy 6
Cerebrovascular Accident 3
Stroke 2
Cardiovascular Disease 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Aggrenox
Intervention Trials
Stroke 4
Atherosclerosis 1
Lupus Erythematosus, Systemic 1
Pure Autonomic Failure 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Aggrenox

Trials by Country

Trials by Country for Aggrenox
Location Trials
United States 54
Canada 9
Australia 4
Japan 2
Germany 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Aggrenox
Location Trials
Tennessee 3
Texas 2
North Carolina 2
Missouri 2
Massachusetts 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Aggrenox

Clinical Trial Phase

Clinical Trial Phase for Aggrenox
Clinical Trial Phase Trials
Phase 4 3
Phase 3 4
Phase 1/Phase 2 1
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Aggrenox
Clinical Trial Phase Trials
Completed 12
Recruiting 2
Not yet recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Aggrenox

Sponsor Name

Sponsor Name for Aggrenox
Sponsor Trials
Boehringer Ingelheim 11
Vanderbilt University Medical Center 2
Maine Medical Center 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Aggrenox
Sponsor Trials
Other 20
Industry 13
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Baxter
McKinsey
Express Scripts
AstraZeneca
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.